Dividend Assets Capital’s AstraZeneca AZN Stock Holding History

Dividend Assets Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-375	Closed	-$51K	–	158
2023 Q4	$51K	Hold	375	–	–	0.01%	258
2023 Q3	$51K	Hold	375	–	–	0.01%	261
2023 Q2	$54K	Hold	375	–	–	0.01%	262
2023 Q1	$51K	Hold	375	–	–	0.01%	279
2022 Q4	$51K	Hold	375	–	–	0.01%	279
2022 Q3	$41K	Hold	375	–	–	0.01%	292
2022 Q2	$50K	Hold	375	–	–	0.01%	284
2022 Q1	$50K	Hold	375	–	–	0.01%	297
2021 Q4	$44K	Hold	375	–	–	0.01%	306
2021 Q3	$45K	Hold	375	–	–	0.01%	302
2021 Q2	$45K	Hold	375	–	–	0.01%	312
2021 Q1	$37K	Hold	375	–	–	0.01%	325
2020 Q4	$37K	Buy	+375	New	+$39.7K	0.01%	314

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dividend Assets Capital's AZN Position: Q1 2024 in Review

Dividend Assets Capital sold out of AstraZeneca (AZN) in Q1 2024, closing a stake of 375 shares — an estimated $51K sold.

Dividend Assets Capital first reported a position in AZN in Q4 2020 and held it in 13 quarters. The position peaked at $54K in Q2 2023. 1,142 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

Dividend Assets Capital reported no remaining AstraZeneca position as of Q1 2024 after selling out during the quarter.
Dividend Assets Capital sold 375 AstraZeneca shares in Q1 2024, an estimated $51K.
Dividend Assets Capital first reported a position in AstraZeneca in Q4 2020 and held it in 13 quarters.
Dividend Assets Capital's AstraZeneca position peaked at $54K in Q2 2023.
1,142 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on Dividend Assets Capital's 13F filing for Q1 2024, filed 15 May 2024.